Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Top Cited Papers
- 1 November 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 394 (10212), 1915-1928
- https://doi.org/10.1016/s0140-6736(19)32591-7
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approachesESMO Open, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Multiple Testing in Group Sequential Trials Using Graphical ApproachesStatistics in Biopharmaceutical Research, 2013
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour siteRadiotherapy and Oncology, 2011
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- The Efficiency of Cox's Likelihood Function for Censored DataJournal of the American Statistical Association, 1977